Zucara Therapeutics Announces Strategic Investment from Sanofi as Part of US$20 M Series B Financing

Zucara Therapeutics, a diabetes life sciences company developing ZT-01, the first once-daily therapeutic to prevent hypoglycemia (low blood glucose levels) in people with diabetes, recently announced that Sanofi has made a strategic investment in Zucara as part of the Company’s US$20 million Series B financing.

Zucara Therapeutics is an OBIO® member, an alumnus of the CAAP® program, and presented at the OBIO® Investment Summit.